United Arab Emirates Approves Oral Medication for Vitiligo for the First Time

The United Arab Emirates has become the first country to approve an oral medication for treating vitiligo, a condition characterized by the loss of skin pigment. The approval, granted on August 17, 2026, by the Emirates Drug Establishment, pertains to Rinvoq (upadacitinib), an immunomodulatory drug designed to address certain immune system mechanisms linked to inflammatory conditions.

This new treatment option is intended for adults and adolescents over 12 years of age who have non-segmental vitiligo and require systemic therapy.

Traditionally, vitiligo treatment has primarily involved topical medications and phototherapy, strategies that target specific areas of skin discoloration and work to repigment affected areas. The introduction of an oral medication could offer expanded therapeutic alternatives for some patients, although the decision to use this treatment will depend on individual medical assessments.

Vitiligo is a chronic skin disorder in which melanin-producing cells, known as melanocytes, are destroyed, resulting in depigmented patches of skin. This condition is not contagious and is not inherently life-threatening; however, it can significantly affect an individual's self-esteem and quality of life. Non-segmental vitiligo, the type covered by the new Rinvoq authorization, tends to affect both sides of the body symmetrically and can vary in the extent of pigment loss.

Rinvoq's active ingredient, upadacitinib, belongs to the class of Janus kinase inhibitors (JAK inhibitors). By targeting specific immune system signals involved in inflammation and autoimmune responses, this medication aims to modulate the immune activity that contributes to melanocyte destruction. The approved dosage involves taking one tablet daily for adults and adolescents aged 12 and above who meet the prescribed medical criteria.

Despite the promising implications of this new treatment option, it is important to note that Rinvoq is not suitable for every patient with vitiligo. The appropriateness of the medication should be determined by factors such as the patient's age, the severity and extent of the vitiligo, individual medical history, and the necessity of systemic treatment.

As with other JAK inhibitor medications, potential side effects may include infections, alterations in certain health parameters, and changes in cholesterol levels. Consequently, this oral medication should only be used under the supervision of a qualified healthcare professional.